Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study - Top-Institutions - MDSpire

Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study

  • By

  • Bingqian Huang

  • Yawen Wang

  • Yubin Li

  • Jiahui Mao

  • Ruixue Wang

  • Gaoyu Lv

  • Ming Hou

  • Yan Shi

  • June 18, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Qilu Hospital of Shandong University
    Qilu Hospital of Shandong University

    Jinan, Shandong

    Key Differentiators

    • Hematology Oncology

  • #2

    Qilu Hospital, Shandong University
    Qilu Hospital, Shandong University

    Jinan, Shandong

    Key Differentiators

    • Hematology Oncology

  • #3

    Children’s Oncology Group
    Children’s Oncology Group

    Arcadia, California

    Key Differentiators

    • Hematology Oncology

  • #4

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology Oncology

  • #5

    St. Jude Children’s Research Hospital
    St. Jude Children’s Research Hospital

    Memphis, Tennessee

    Key Differentiators

    • Hematology Oncology

Original Source(s)

Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study

  • by Bingqian Huang, Yawen Wang, Yubin Li, Jiahui Mao, Ruixue Wang, Gaoyu Lv, Ming Hou, Yan Shi

  • June 18, 2026

Related Content

Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis

Correction: Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies – a comprehensive review

PRDM1-mediated epigenetic and transcriptional repression mechanisms: a key hub in immune differentiation, tumor progression, and inflammatory responses